Ranbaxy surprises with Q4 loss, sees modest sales growth in 2013

MUMBAI Tue Feb 26, 2013 4:21pm IST

A patient holds free medicine provided by the government at Rajiv Gandhi Government General Hospital (RGGGH) in Chennai July 12, 2012. REUTERS/Babu/Files

A patient holds free medicine provided by the government at Rajiv Gandhi Government General Hospital (RGGGH) in Chennai July 12, 2012.

Credit: Reuters/Babu/Files

Related Topics



MUMBAI (Reuters) - Ranbaxy Laboratories Ltd(RANB.NS), India's top drugmaker by sales, said its base business would grow a modest 10 percent in 2013 after reporting a surprise quarterly loss on product recall charges, sending its shares down more than 4 percent.

Controlled by Japan's Daiichi Sankyo Co (4568.T), Ranbaxy reported a quarterly net loss of 4.92 billion rupees after setting aside 1.86 billion rupees towards recall costs. Analysts on average had estimated consolidated net profit at 1.44 billion rupees on net sales of 26.96 billion rupees, according to Thomson Reuters I/B/E/S.

The drugmaker in November voluntarily recalled its cholesterol lowering generic of Lipitor from the U.S. market after it discovered contamination with tiny glass particles in certain lots of 10mg, 20mg and 40mg doses of the drug.

"This is really bad. This raises serious questions about transparency," said Daljeet Kohli, head of research at brokerage IndiaNivesh. "The company has been saying that this recall was voluntary and now it has made a huge provision for costs, which is not a good thing for any company to do."

After the product recall, Ranbaxy's market share of generic Lipitor fell to less than 3 percent, according to industry estimates. The drugmaker has now resumed supplying the United States.

Ranbaxy launched the first generic version of Pfizer's (PFE.N) Lipitor in 2011 and during its first six months on the market the company generated sales of nearly $600 million, according to analysts estimates.

The company said it expects to achieve sales of over 120 billion rupees in the current fiscal year ending December, compared to 124.6 billion rupees reported in 2012.


Ranbaxy said consolidated sales fell 28.8 percent to 26.71 billion rupees in the fiscal fourth quarter ended December. Sales in its key North America market fell to 8.51 billion rupees in October-December compared to $407 million in the year earlier when the company gained from exclusive rights to sell generic Lipitor in the United States.

Global demand for cheaper generic medicines from companies like Ranbaxy and local rivals Dr. Reddy's Laboratories Ltd (REDY.NS), Cipla Ltd (CIPL.NS) and Sun Pharmaceutical Industries Ltd (SUN.NS) is booming as developed nations battle rising healthcare costs.

The drugmakers however, face intense competition as well as an increase in lawsuits from rival drugmakers and a stricter U.S. regulatory environment.

Valued at $3.2 billion, shares in Ranbaxy fell 3.95 percent at 416.70 rupees on Tuesday when the Mumbai market was down 1.64 percent. The shares have fallen 17.6 percent this year compared to a 3.2 percent drop in the BSE healthcare index.

(Reporting by Kaustubh Kulkarni; Editing by Matt Driskill)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Shares Hit Record

Sensex, Nifty rise to second consecutive record high

Sensex surges 500 points on BOJ easing, L&T gains

The BSE Sensex and Nifty surged to record highs for a second consecutive session on Friday after Bank of Japan's surprise expansion of its massive stimulus programme raised hopes for additional foreign inflows, boosting blue-chips such as Larsen & Toubro.  Full Article 


Indian Economy

Indian Economy

India's fiscal deficit in H1 almost 83 pct of full-year target.  Full Article 

M&M Earnings

M&M Earnings

M&M Q2 net profit down 4 percent, hit by poor monsoon.  Full Article 

Ban on E-Cigs?

Ban on E-Cigs?

Govt considers ban on e-cigarettes, sale of single smokes.  Full Article 



Silver futures in India hit four-year low on global cues.  Full Article 

BOJ Policy

BOJ Policy

BOJ shocks markets with surprise easing as inflation slows.  Full Article 

Shadow Banking

Shadow Banking

China's shadow banking sector growing rapidly, third largest in world - FSB.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage